Last reviewed · How we verify
Topocaine — Competitive Intelligence Brief
phase 2
cyclomethycaine
Sodium channel alpha subunits; brain (Types I, II, III)
Neuroscience
Small molecule
Live · refreshed every 30 min
Target snapshot
Topocaine (CYCLOMETHYCAINE). Topocaine blocks sodium channels in the brain to prevent pain signals from being transmitted.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Topocaine TARGET | CYCLOMETHYCAINE | phase 2 | cyclomethycaine | Sodium channel alpha subunits; brain (Types I, II, III) |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (cyclomethycaine class)
- · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Topocaine CI watch — RSS
- Topocaine CI watch — Atom
- Topocaine CI watch — JSON
- Topocaine alone — RSS
- Whole cyclomethycaine class — RSS
Cite this brief
Drug Landscape (2026). Topocaine — Competitive Intelligence Brief. https://druglandscape.com/ci/cyclomethycaine. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing